Provided by Tiger Trade Technology Pte. Ltd.

REVVITY INC

124.75
+0.62000.50%
Post-market: 124.750.00000.00%19:44 EDT
Volume:2.29M
Turnover:283.97M
Market Cap:13.95B
PE:59.57
High:124.97
Open:124.48
Low:121.51
Close:124.13
52wk High:124.97
52wk Low:81.22
Shares:111.80M
Float Shares:102.00M
Volume Ratio:1.78
T/O Rate:2.24%
Dividend:0.28
Dividend Rate:0.22%
EPS(TTM):2.09
EPS(LYR):2.07
ROE:3.21%
ROA:2.37%
PB:1.93
PE(LYR):60.30

Loading ...

BUZZ-Revvity rises after first-quarter profit beat

Reuters
·
May 05

Stock Track | Revvity Soars 6.24% Intraday on Strong Q1 Earnings Beat and Strategic China Business Divestiture

Stock Track
·
May 05

Revvity Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Revvity Exec Says Seasonal Uptick Seen From Q1 to Q2; Margins Expected to Rise to About 29% in Q3 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says China Diagnostics Demand, Pricing Hit by Policy Headwinds - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Plans to Remain Prudent With Its Forward-Looking Assumptions - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co's Immuno-Diagnostics Business Declined in the Low Single Digits Organically in Q1 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Expects Q2 Organic Growth to Be in the Range of 2% to 3% - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Exepcts a Continuation, IF Not Acceleration, of Life Sciences Performance in Chine Through 2026 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Saw Positive Growth From Pharma and Academic Customer for the First Time Since Q2 2023 - Conf Call

THOMSON REUTERS
·
May 05

Revvity trims annual profit, sales forecast to exclude China immunodiagnostics unit

Reuters
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Adjusted EPS Range $5.20-$5.30, vs. FactSet Est of $5.39

MT Newswires Live
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Pro Forma Revenue Range $2.81B-$2.84B

MT Newswires Live
·
May 05

Revvity Q1 Adj. EPS $1.06 Beats $1.02 Estimate, Sales $711.118M Beat $705.134M Estimate.

Benzinga Earnings
·
May 05

Revvity Q1 GAAP EPS rises 5.7% to $0.37; revenue climbs 6.9% to $711 million

Reuters
·
May 05

BRIEF-Revvity Q1 Adjusted EPS USD 1.04 Vs. IBES Estimate USD 1.02

Reuters
·
May 05

Corrected-Revvity Q1 Adjusted EPS Continuing Operations USD 1.06 (Corrects Amount)

THOMSON REUTERS
·
May 05

Revvity Inc - Enters Letter of Intent to Divest China Immunodiagnostics; Definitive Agreement Expected Q2 2026

THOMSON REUTERS
·
May 05

Revvity Outlook FY Revenue USD 2,810-2,840 Million

THOMSON REUTERS
·
May 05

Revvity Outlook FY Adjusted EPS USD 5.2-5.3

THOMSON REUTERS
·
May 05